APON(SZ:300753)2026-01-11 15:10Company Overview - Aipeng Medical focuses on medical devices, specializing in pain management and upper airway management, while also exploring brain-computer interface innovations [5] - The company has a strategic partnership with Ruishen'an Medical, a leading player in the neuroregulation field in China [5] Product Competitiveness - The "Multimodal ADHD Behavioral Training System" integrates data connectivity between in-hospital and home training environments, addressing both medication and behavioral training as primary treatment options [6] - The system aims to provide a comprehensive training solution, mitigating risks associated with traditional single behavioral training products [6] Clinical Applications - The Persistent Insomnia Anesthesia Treatment System has been implemented in hospitals, showing promising treatment outcomes and attracting interest from sleep and anesthesia specialists [7] - The company’s EEG collection products are essential components of the ADHD treatment system, with relevant pricing established in various provinces [9] Future Investments - Aipeng Medical plans to continue exploring brain-computer interface opportunities aligned with its strategic direction, focusing on sensor technology, signal processing, and clinical applications for mental health disorders [10] - The establishment of an AI and Brain-Computer Engineering Research Institute aims to drive innovation in pain management, anesthesia, and mental health diagnostics [10] Business Progress of Ruishen'an - Ruishen'an has successfully launched several products, including the implantable vagus nerve stimulator and the rechargeable spinal cord stimulator, generating revenue [11] - The first domestic implantation of a closed-loop neurostimulation system for Parkinson's disease is expected to occur by the end of 2025, marking a significant advancement in clinical practice [11]